Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BIIBthis companyBiogen Inc.	$256.57	19.89×	1.41×	2.63×	10.1×	102.9%	70.5%	19.1%	13.2%	7.1%	6.6%	7.9%	0.38×	1.34×	7.63×	2.68×	0.0%	5	3.15	3	B
ALNYAlnylam Pharmaceuticals, Inc.	$156.13	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
AMGNAmgen Inc.	$463.50	22.84×	20.34×	4.79×	13.11×	92.1%	70.8%	29.1%	21.0%	89.1%	13.2%	4.6%	6.31×	2.69×	3.88×	1.14×	2.9%	8	2.44	3	B+
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
LLYEli Lilly and Company	$1,396.54	46.58×	36.37×	14.81×	31.57×	-47.2%	83.0%	45.6%	31.7%	77.8%	30.2%	0.9%	1.6×	1.12×	37.34×	1.58×	0.6%	7	9.47	3	B
PFEPfizer Inc.	$29.31	18.31×	1.64×	2.26×	12.38×	19.3%	74.3%	27.8%	12.4%	9.0%	10.0%	6.4%	0.78×	3.95×	6.52×	1.16×	6.9%	6	2.16	3	B
Peer median	—	22.84×	25.88×	13.41×	13.11×	-47.2%	81.8%	27.8%	12.4%	39.8%	13.2%	0.9%	1.62×	1.12×	3.88×	1.58×	0.6%	6	2.44	3	—